Research Article

Logistic regression analysis of ultrasound findings in predicting the malignant and benign phyllodes tumor of breast

Tingting Li*, Yanjie Li‡, Yingqi Yang‡, Juan Li‡, ZiYue Hu‡, Lu Wang‡, Wei Pu‡, Ting Wei‡, Man Lu‡*†

Department of Ultrasound, Sichuan Cancer Hospital Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

* These authors contributed equally to this work.
‡ YL, YY, JL, ZH, LW, WP, TW and ML also contributed equally to this work.
* graceof@163.com

Abstract

Objective

To evaluate ultrasound characteristics in the prediction of malignant and benign phyllodes tumor of the breast (PTB) by using Logistic regression analysis.

Methods

79 lesions diagnosed as PTB by pathology were analyzed retrospectively. The ultrasound features of PTB were recorded and compared between benign and malignant tumors by using single factor and multiple stepwise Logistic regression analysis. Moreover, the Logistic regression model for malignancy prediction was also established.

Results

There were 79 patients with PTB, including 39 benign PTBs and 40 malignant PTBs (33 borderline PTBs and 7 malignant PTBs by pathologic classification). The area under the ROC curve (AUC) of lesion size and age were 0.737 and 0.850 respectively. There were significant differences in age, lesion size, shape, internal echo, liquefaction, and blood flow between malignant and benign PTBs by using single-factor analysis (P<0.05). Age, internal echo, and liquefaction were significant features by using Logistic regression analysis. The corresponding regression equation ln (p/(1 - p)) = -3.676+2.919 internal echo +3.029 liquefaction +4.346 age).

Conclusion

Internal echo, age, and liquefaction are independent ultrasound characteristics in predicting the malignancy of PTBs.
Introduction
Phyllodes tumors of the breast (PTBs) are rare fibroepithelial tumors and account for less than 1% of all breast neoplasms [1, 2]. They are typically presented as a leaf-like pattern with combined features from both epithelial lesion and mesenchymal lesion in microscopy. Histologically, depending on their mitotic activity, stromal characteristics, and degree of cellular atypia, the biological behavioral gamut of PTBs ranges from benign, borderline to malignant [3]. The majority of PTBs are benign ones. Among the resected PTBs, benign, borderline and malignant PTBs accounted for 60%, 20%, and 20%, respectively [4, 5]. Surgery is the standard treatment of PTB. Recurrence rates of borderline and malignant PTBs are relatively higher than benign ones [6]. Wide excision of all types of phyllodes is necessary to avoid local recurrence and subsequent surgery, especially for borderline and malignant ones [7, 8]. Furthermore, malignant PTB can metastasize to the lungs, bones, and pleura, which may have fatal effects on patients [9]. Therefore, the pre-operation diagnosis is important for the treatment of PTB.

Ultrasonography (US), mammography, and magnetic resonance imaging (MRI) are considered as the main pre-operative diagnostic methods for PTB. According to previous studies, mammography was inconclusive for differentiating the pathologic grades of PTBs [10, 11]. Several MRI findings or parameters, such as low apparent diffusion coefficient (ADC) and tumor signal intensity, can be used to help determine the histologic grade of PTB [12–14]. However, there are very limited studies available focusing on the US characteristics of PTB [15, 16].

To our knowledge, no studies had been conducted to investigate the possible correlations between US findings and the histologic grades of PTB. In this study, we propose to investigate the capability of US characteristics in predicting benign (pathologically classified as benign PTB) and malignant PTB (pathologically classified as borderline or malignant PTB).

Materials and methods

Patients
This study was approved by the Institutional Review Board and Ethics Committee of Sichuan Cancer Hospital (SCCHEC-03-2017-010). All patients signed written informed consent before the examination.

From January 2017 to September 2020, a total of 79 consecutive patients with 79 lesions were enrolled in this study. The inclusion criteria were as follows: (1) all PTB should be classified as different risk levels by post-operative pathology (i.e. benign, borderline, or malignant); (2) patients’ medical history and US images were all complete and comprehensive. The exclusion criteria were as follows: (1) unsatisfied US image quality or incomplete vascular information; (2) recurrent PTB were not enrolled in this study.

Equipments
Aixplorer US diagnostic imaging system (SuperSonic Imagine, Aixen Provence, France), Philips iU Elite, Epiq5 system (Philips Medical Systems, Bothell, WA), GE Logiq E9, and Mylab Twice were used. All systems were equipped with a high-frequency linear array probe (4–13 MHz) and a convex transducer (1–5 MHz).

US characteristics of PTB
The US characteristics of PTB in this study include shape (regular or lobulated), margin (well defined or ill-defined), size (the largest diameter of the lesion), internal echo (homogeneous or
heterogeneous), vascularity (poor: Adler classification 0-II; or abundant: Adler classification III) and liquefaction (present or absent).

Statistical analysis
Categorical data were presented with frequency and percentage. Fisher’s exact test was used to compare categorical variables. Continuous data were presented with mean and standard deviation. Receiver operating characteristic (ROC) curves analysis was performed to estimate the capability of different variables in predicting the malignancy of PTB. A multivariate logistic regression model, including statistically significant risk factors in predicting the malignancy of PTB, was also established.

Results
A total of 79 cases of PTB were reviewed in this study, including 39 benign and 40 malignant ones. Patients with malignant PTB were elder than those with benign PTB (48.0 vs. 34.8, \( p < 0.001 \)). Compared with benign PTB, the lesion size of malignant PTB was larger (3.19cm vs. 5.3cm, \( p < 0.001 \)). Moreover, malignant PTBs were presented in lobulated shape, with heterogeneous inner echo as well as abundant vascularity in the tumor. In addition, malignant PTBs showed more liquefactions in the tumor than benign ones (Table 1).

In ROC curve analysis, the area under the curve (AUC) for patient age and lesion size were 0.85 and 0.73, separately. The optimal cut-off value was 4.45cm for lesion size and 46.5 for patient age (Fig 1) (Table 2). The age had a higher AUC in the differential diagnosis of PTBs compared with lesion size. However, the difference was not statistically significant (0.85 vs 0.73, \( P = 0.1 \)).

In multivariate logistic regression, age (\( >46.5 \), 95% confidence interval [CI] 7.14–834.3), liquefaction (with liquefaction, 95% CI 1.92–222.5), and inner echo (heterogeneous, 95% CI 1.93–177.9) emerged as independent predictors for differentiating between malignant and benign PTB (Table 3) (Figs 2 and 3).

| Table 1. Characteristics comparison between malignant and benign PTBs. |
|----------------------|----------------------|----------------------|
|                      | Benign PTB            | Malignant PTB         | \( P \) value |
| Age                  | 34.8±10.3             | 48.0±9.2              | 0.0001       |
| Size (cm)            | 3.19±1.94             | 5.32±3.42             | 0.001        |
| Margin well-defined ill-defined) |                      |                      | 0.003        |
| well defined         | 25                    | 12                    |              |
| ill-defined          | 14                    | 28                    |              |
| Shape                |                       |                       | 0.001        |
| regular              | 24                    | 10                    |              |
| lobulated            | 15                    | 30                    |              |
| Internal-echoecheeechoeheterogeneous) |                      |                      | 0.0001       |
| homogeneous          | 31                    | 6                     |              |
| heterogeneous        | 8                     | 34                    |              |
| Liquefaction         |                       |                       | 0.0001       |
| absent               | 38                    | 16                    |              |
| present              | 1                     | 24                    |              |
| Vascularity          |                       |                       | 0.007        |
| poor                 | 33                    | 22                    |              |
| abundant             | 6                     | 18                    |              |

https://doi.org/10.1371/journal.pone.0265952.t001
Phyllodes tumor is a rare breast tumor with heterogeneous fibroepithelial. It constitutes a wide range of tumors, from benign to malignant [17]. A higher recurrence rate is observed in borderline and malignant tumors, which also had a higher tendency to systemic metastasis compared with benign ones. Due to various biological behaviors of PTB, wider surgical excision is needed especially for borderline and malignant PTB, which may further require chemotherapy and adjuvant radiation therapy treatment [18]. Given these reasons, a preoperative diagnosis is

**Table 2. Diagnostic performance of age and size in differentiating PTBs.**

| Cut-off value | AUC | Sen(%) (95%CI) | Spe(%) (95%CI) |
|---------------|-----|---------------|---------------|
| age           | 46.5| 0.85          | 68.3 (51.9,81.9) | 94.9 (82.7,99.4) |
| size          | 4.45| 0.74          | 51.2 (35.1,67.1) | 84.6 (69.5,94.1) |

**Table 3. Multivariate analysis with significant factors.**

| Reference          | Odds ratio | 95%CI           | P value |
|--------------------|------------|-----------------|---------|
| Internal echo      | heterogeneous | 2.919 (1.93,177.95) | 0.01 |
| Liquefaction       | With liquefaction | 3.029 (1.92,222.47) | 0.01 |
| Age                | >46.5      | 4.346 (7.14,834.32) | 0.00 |
vital for the choice of PTB treatment. However, there are very limited related studies available investigating different imaging features between benign and malignant PTBs.

According to previous studies, benign PTB is more common and accounts for 60–75% of all PTBs [19, 20]. The percentage of malignant PTB in our study, however, was slightly more than that of benign one (51% vs. 49%), which is inconsistent with prior studies. This difference might relate to the fact that most cases in our study were categorized with high BI-RADS category before surgery (30 cases were categorized as BI-RADS 3, 49 cases were 4 and above). Nearly half of the patients enrolled in our study were referred from other hospitals or institutions for a second diagnostic opinion, meaning that they had been screened and had a high suspicion of malignancy.

Most patients affected by PTB were between the ages of 35 and 55. The overall mean age of patients in our study was 41.4 years, with malignant tumors developed later than benign ones (48.0 years vs. 34.8 years). There was a statistical difference in patient age between benign and malignant tumors (p < 0.001). The lesion size of these two types of tumors is also statistically different, where malignant PTB had a larger size (3.19 cm vs. 5.3 cm, p < 0.001) than benign one. These findings concur with previous literatures that malignant PTB is associated with larger lesion size and elder patient age [21].

US characteristics associated with tumor types, including shape, margin, internal echo, vascularity and liquefaction were also investigated. All these US characteristics turned out to be statistically different between malignant and benign tumors. To summarize, we found that malignant PTBs were presented in lobulated shape, with heterogeneous inner echo as well as abundant vascularity in the tumor. In addition, there were more liquefactions in malignant tumors than in benign ones.

Some previous studies have also noted that irregular masses with non-circumscribed margins might be related to malignant PTB. The complex cystic echogenicity was found to be

Fig 2. US images of benign PTBs. a) A 44 years old woman with a 3.2 cm PTB in her left breast; b) A 32 years old woman with a 2.6 cm PTB in her right breast; c) A 52 years old woman with a 2.6 cm PTB in her left breast; d) A 28 years old woman with a 9.6 cm PTB in her right breast. All these images showed regular tumors with homogeneous inner echo, without liquefaction in the tumor (even in a 9.6 cm tumor).

https://doi.org/10.1371/journal.pone.0265952.g002
helpful in the differentiation of malignant and benign phyllodes tumors [15, 22]. However, the differences in internal echo and vascularity between malignant and benign PTB have not been noted yet.

We proposed that, for lesion size, the optimal cut-off value between benign and malignant was 4.45cm, with a sensitivity of 51.2% and a specificity of 84.6%, respectively. Liberman et al. noted that phyllodes tumors larger than 3 cm had a higher likelihood of being malignant [10]. Megan et al. identified phyllodes tumor larger than 7 cm as an indication of an increased likelihood of being malignant [22]. Our threshold is in the middle of these previous results. In our series, half of the benign PTBs were less than 3cm in lesion size (21/39, 53.8%), and only 20% (8/40) of the malignant PTBs were with lesion size larger than 7cm. Therefore, the threshold we proposed would be more meaningful in malignancy diagnosis. Moreover, the cut-off value of patient age we proposed in this study was 46.5 years, with a sensitivity of 68.3% and a specificity of 94.9%, respectively. This cut-off value is younger than a previous study, which reported that patients older than 55 indicated a higher likelihood of malignant phyllodes tumors [22].

In our study, according to results of stepwise LR, age (>46.5), liquefaction (with liquefaction), and heterogeneous inner echo emerged as independent risk factors for malignant PTB. Previous studies had productive discussions on the correlation between patient age and the pathological grade of PTB, but no consistent conclusions have been drawn. Some studies suggested that the age of patients was not related to the pathological grade of PTB, but other relevant studies believed that malignant PTB was more common in elderly patients aged from 45 to 54 years old. The latter studies found that the increase of age was related to the increase of the pathological grade of PTB, which is similar to our findings. At present, few studies have reported on the correlations between internal echo and PTB malignancy. The findings of our study indicated that the number of cases of malignant PTB with inhomogeneous internal (34/
40) was much higher than that of benign PTBs (8/39). In other words, heterogeneous inner echo helped distinguish benign from malignant phyllodes tumors. This finding is similar to the results of the study by Chao et al. [16].

Liquefaction was also associated with malignant PTB in our findings. Yabuuchi’s study confirmed that the cystic change on MRI can help determine the histologic grade of breast PTB [12]. Other studies also reported that malignant PTB demonstrated with more cystic space and heterogeneous inner echo on ultrasound [23, 24]. Our study showed that liquefaction, which is probably caused by the continuous and rapid growth of tumor cells and stromal cells, can be considered as an independent risk factor for malignant PTB.

This study had some limitations as well. First, this is a retrospective study with a relatively small sample size. Current results showed that US characteristics such as size and shape had no significance in differentiating between malignant and benign PTBs. All these might be further evaluated with greater sample sizes and a longer follow-up period. Meanwhile, a large-scale prospective study is required to verify the clinical value of our prediction model.

Conclusion

In conclusion, the internal echo, age, and liquefaction can be used for a noninvasive risk level prediction model for PTB. This model may help identify the different pathological grades of PTB before surgery.

Supporting information

S1 Data.
(XLSX)

Author Contributions

Conceptualization: Tingting Li.
Data curation: Tingting Li.
Formal analysis: Tingting Li, Juan Li, Ting Wei.
Investigation: Tingting Li, Lu Wang, Wei Pu.
Methodology: Tingting Li, Lu Wang, Man Lu.
Project administration: Juan Li.
Resources: Yanjie Li.
Software: Yingqi Yang, Ting Wei.
Supervision: ZiYue Hu.
Validation: Yanjie Li, ZiYue Hu, Wei Pu.
Visualization: ZiYue Hu.
Writing – original draft: Tingting Li.
Writing – review & editing: Man Lu.

References

1. Michael et al., “Phyllodes tumors,” Am. J. Surg., 1993.
2. Tse G., Niu Y., and Shi H. J., “Phyllodes tumor of the breast: an update.” *Breast Cancer*, vol. 17, no. 1, p. 29, 2010. https://doi.org/10.1007/s12282-009-0114-z PMID: 19434472

3. Choi J. and Koo J. S., “Comparative study of histological features between core needle biopsy and surgical excision in phyllodes tumor,” *Pathol. Int.*, vol. 62, no. 2, pp. 120–126, 2012. https://doi.org/10.1111/j.1440-1827.2011.02761.x PMID: 22243782

4. Chen W. H., Cheng S. P., Tzen C. Y., Yang T. L., and Liu T. P., “Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases.” *J. Surg. Oncol.*, vol. 91, no. 3, pp. 185–194, 2010.

5. Rosen P., Obermann H. A., Roai J., and Sobin L. H., “Fibroepithelial neoplasms,” 1993.

6. Hassouna J. B. et al., “Phyllodes tumors of the breast: a case series of 106 patients.” *Am. J. Surg.*, vol. 192, no. 2, pp. 141–147, 2006. https://doi.org/10.1016/j.amjsurg.2006.04.007 PMID: 16860620

7. Lee A., Hodl Z., Ellis I. O., and Elston C. W., “Histological features useful in the distinction of phyllodes tumour and fibroadenoma on needle core biopsy of the breast,” *Histopathology*, vol. 51, no. 3, pp. 336–344, 2010.

8. Dillon M. F., Quinn C. M., Mcdermott E. W., O’Doherty A., O’Higgins N., and Hill A., “Needle core biopsy in the diagnosis of phyllodes neoplasm,” *Surgery*, vol. 140, no. 5, pp. 779–784, 2006. https://doi.org/10.1016/j.surg.2006.03.022 PMID: 17084721

9. Guerrero M. A., Ballard B. R., and Grau A. M., “Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth,” *Surg. Oncol.*, vol. 12, no. 1, pp. 27–37, 2003. https://doi.org/10.1016/s0960-7404(03)00005-7 PMID: 12689688

10. Liberma L., Bonaccio E., Hamele-Benat D., Abramson A. F., Cohen M. A., and Dershaw D. D., “Benign and malignant phyllodes tumors: mammographic and sonographic findings,” *Radiology*, vol. 198, no. 1, pp. 121–124, 1996. https://doi.org/10.1148/radiology.198.1.8539362 PMID: 8539362

11. Duman L. et al., “Differentiation between Phyllodes Tumors and Fibroadenomas Based on Mammographic Sonographic and MRI Features,” *Breast Care*, vol. 11, no. 2, pp. 123–127, 2016. https://doi.org/10.1159/000444377 PMID: 27239174

12. Yabuchi H. et al., “Phyllodes tumor of the breast: correlation between MR findings and histologic grade,” *Radiology*, vol. 241, no. 3, p. 702, 2006. https://doi.org/10.1148/radiol.241051470 PMID: 17032912

13. Fanria D. M., Gorczyca D. P., Barsky S. H., Sinha S., and Bassett L. W., “Benign phyllodes tumor of the breast: retrospective review of 170 cases,” *Am. J. Surg.*, vol. 198, no. 5, pp. 916, 1996. https://doi.org/10.1007/s12282-011-0276-x PMID: 22243782

14. Reinfuss M., Mitu J., Duda K., Stelmach A., Ry J., and Smolak K., “The treatment and prognosis of patients with phyllodes tumor of the breast: An analysis of 170 cases,” *Cancer*, vol. 77, no. 5, pp. 910–916, 1996. https://doi.org/10.1002/(sici)1097-0142(19960301)77:5<910::aid-cncr16>3.0.co;2-6 PMID: 8608483

15. Youn I., Choi S. H., Moon H. J., Min J. K., and Kim E. K., “Phyllodes Tumors of the Breast: Ultrasonographic Findings and Diagnostic Performance of Ultrasound-Guided Core Needle Biopsy,” *Ultrasound Med. Biol.*, vol. 39, no. 6, pp. 987–992, 2013. https://doi.org/10.1016/j.ultrasmedbio.2013.01.004 PMID: 23499344

16. Chao T. C., Lo Y. F., Chen S. C., and Chen M. F., “Sonographic features of phyllodes tumors of the breast,” *Ultrasound Obstet. Gynecol.*, vol. 20, no. 1, pp. 64–71, 2002. https://doi.org/10.1046/j.1445-0055.2002.00736.x PMID: 12100421

17. Reinfuss M., Mitu J., Duda K., Steimach A., Ry J., and Smolak K., “The treatment and prognosis of patients with phyllodes tumor of the breast: An analysis of 170 cases,” *Cancer*, vol. 77, no. 5, pp. 910–916, 1996. https://doi.org/10.1002/(sici)1097-0142(19960301)77:5<910::aid-cncr16>3.0.co;2-6 PMID: 8608483

18. Barth R. J., Wells W. A., Mitchell S. E., and Cole B. F., “A Prospective, Multi-Institutional Study of Adjunct Radiotherapy After Resection of Malignant Phyllodes Tumors,” *Ann. Surg. Oncol.*, vol. 16, no. 8, pp. 2288–2294, 2009. https://doi.org/10.1245/s10434-009-0489-2 PMID: 19424757

19. Jacklin R. K., Ridgway P. F., Ziprin P., Healy V., Hadjiminas D., and Darzi A., “Optimising preoperative diagnosis in phyllodes tumour of the breast,” *J. Clin. Pathol.*, vol. 59, no. 5, pp. 454–459, 2006. https://doi.org/10.1136/jcp.2005.025866 PMID: 16461806

20. Onkendi E. O., Jimenez R. E., Spears G. M., Harmsen W. S., Ballman V K., and Hieken T. J., “Surgical Treatment of Borderline and Malignant Phyllodes Tumors: The Effect of the Extent of Resection and Tumor Characteristics on Patient Outcome,” *Ann. Surg. Oncol.*, vol. 21, no. 10, pp. 3304–3309, 2014. https://doi.org/10.1245/s10434-014-3909-x PMID: 25034817

21. Efared B., Ebang G. A., Tahiri L., Sidibé I. S., and El Fatemi H., “Phyllodes tumors of the breast: clinicopathological analysis of 106 cases from a single institution,” *Breast Dis*, vol. 37, no. 3, 2018. https://doi.org/10.3233/BD-170297 PMID: 29332027
22. Kalambo M. et al., “Phyllodes Tumor of the Breast: Ultrasound-Pathology Correlation,” *Am. J. Roentgenol.*, pp. W1–W7, 2018. https://doi.org/10.2214/AJR.17.18554 PMID: 29412020

23. Hamid S. A. et al., “Radiopathological characteristics and outcomes of phyllodes tumor of the breast in Malaysian women,” *Med. (United States)*, vol. 97, no. 31, 2018, https://doi.org/10.1097/MD.0000000000011412 PMID: 30075507

24. Xiao M. et al., “Local recurrent phyllodes tumors of the breast: Clinical and sonographic features,” *J. Ultrasound Med.*, vol. 34, no. 9, pp. 1631–1638, 2015, https://doi.org/10.7863/ultra.15.14.11012 PMID: 26269294